157 The mTOR kinase inhibitor AZD8055 induces cell death in Her2+ tumours partially or intrinsically resistant to ErbB2 inhibitors

Sarah V. Holt(Pharma Nord (United Kingdom)), Sylvie M. Guichard(Novo Nordisk (United Kingdom)), Edward M. Brown(Harvard University), Robert W. Wilkinson(Immunocore (United Kingdom)), Jonathan R. Dry(AstraZeneca (United Kingdom)), Gayle Marshall(Medicines Discovery Catapult), Zoë Howard(United States Department of Defense), Sarah E. Fenton, Armelle Logié(Sorbonne Université), Dominic I. James(AstraZeneca (United Kingdom))
European Journal of Cancer Supplements
November 1, 2010
Cited by 1


Related Papers